References
- Stefanic M L, Anderson G L, Margolis K L, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–1657
- Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
- Smith D C, Prentice R, Thompson D J, Hermann W L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164–1167
- Ziel H K, Finkle W D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167–1170
- Green P K, Weiss N S, McKnight B, Voigt L F, Beresford S A. Risk of endometrial cancer following cessation of menopausal hormone use. Cancer Causes Control 1996; 7: 575–580
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059
- Ettinger B, Selby J, Citron J T, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83: 693–700
- Weiderpass E, Adami H O, Baron J A, et al. Risk of endometrial cancer following estrogen replacement therapy with and without progestins. J Natl Cancer Inst 1999; 91: 1131–1137
- Ylikorkala O, Wahlström T, Caubel P, Lane R. Intermittent progestin administration as part of hormone replacement therapy; long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate. Acta Obstet Gynecol Scand 2002; 81: 654–660
- Goldstein S R. The case for less-than-monthly progestogen in women on HT: is transvaginal ultrasound the key?. Menopause 2005; 12: 110–113
- Backmann T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005; 106: 813–817
- von Schoultz B. Ultra low dose estradiol and NETA: is a neutral effect on the breast possible? Presented at 11th World Congress on the Menopause, Buenos Aires, October 19th 2005. Climacteric 2005; 8(Suppl 2)228, (Abstr SS-02-04)
- Utian W H, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065–1079
- Ettinger B, Ensrud K E, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004; 104: 443–451